Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: imagobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/28/2022 | $25.00 | Outperform | Wedbush |
| 2/14/2022 | $37.00 | Buy | HC Wainwright & Co. |
| 8/10/2021 | $30.00 | Buy | Jefferies |
| 8/10/2021 | $35.00 | Buy | Guggenheim |
| 8/10/2021 | Outperform | Cowen | |
| 8/10/2021 | $31.00 | Buy | Stifel |
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Michael Arenberg to Chief Operating and Business Officer. Mr. Arenberg is a distinguished biopharmaceutical executive who will be charged with leading strategic operations, investor relations, commercial development and business development of Imago. "I welcome Mike to Imago with great enthusiasm at this important stage of company development," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSc
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu
Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry. "I am pleased to welcome to Laurie to Imago's Board of Directors as the company continues to grow, following our successful IPO in July," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "Laurie brings extensive experience to our Board and we look forward
SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 13G - Imago BioSciences, Inc. (0001623715) (Subject)
15-12G - Imago BioSciences, Inc. (0001623715) (Filer)
EFFECT - Imago BioSciences, Inc. (0001623715) (Filer)
25-NSE - Imago BioSciences, Inc. (0001623715) (Subject)
S-8 POS - Imago BioSciences, Inc. (0001623715) (Filer)
S-8 POS - Imago BioSciences, Inc. (0001623715) (Filer)
POS AM - Imago BioSciences, Inc. (0001623715) (Filer)
8-K - Imago BioSciences, Inc. (0001623715) (Filer)
SC 14D9/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC TO-T/A - Imago BioSciences, Inc. (0001623715) (Subject)
SC 14D9/A - Imago BioSciences, Inc. (0001623715) (Subject)
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatme
- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with baseline loss of heterozygosity (LOH) and follow-up samples showed a reduction in homozygous mutant granulocytes and mutant allele frequencies – -Aligned with FDA on strategy for bomedemstat pivotal
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment - - The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxolitinib in myelofibrosis currently screening patients - REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical c
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago. Upon the successful closing of the tender offer, stockholders of Imago will receive $36 in cash for each share of Imago common stock validly tendered and not validly withdrawn in the offer, without interest and subject to deduction for any required tax withholding. Following the purchase of shares in the tender offer, Imago will merge with and into a subsidiary of Mer
REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hemat
Acquisition expands Merck's growing hematology portfolio Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005295/en/ "We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve," said Robert M
- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities for Bomedemstat pivotal Phase 3 ET and Phase 2 PV trials continuing to advance - REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "Im
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in two upcoming investor conferences. Details of the events are as follows: H.C. Wainwright 3rd Annual Precision Oncology Conference. Dr. Rienhoff will present on Monday, November 14 at 12:30 pm ET. Stifel Healthcare Conference. Dr. Rienhoff will present on Wednesday, November 16th at 8:00 am ET. Interest
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced two abstracts have been accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022. ASH 2022 Presentation Details: Oral Presentation Title: "A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)"Session Name: Myeloproliferative Syndromes: Clinical and
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
4 - Imago BioSciences, Inc. (0001623715) (Issuer)
Wedbush initiated coverage of Imago BioSciences with a rating of Outperform and set a new price target of $25.00
HC Wainwright & Co. initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $37.00
Jefferies initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $30.00
Guggenheim initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $35.00
Cowen initiated coverage of Imago BioSciences with a rating of Outperform
Stifel initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $31.00